Clover Health Investments, Corp. — Q1 2023 Form 10-Q Summary
Business context and reporting period
Clover Health operates Medicare Advantage PPO and HMO plans and a Non-Insurance business under CMS’s ACO REACH model. Its Clover Assistant platform supports physician decision-making and care management. This filing covers the unaudited three months ended March 31, 2023, compared with the same period in 2022.
- Medicare Advantage members at March 31, 2023: 83,794 across eight states and 220 counties.
- Non-Insurance beneficiaries: 53,616, down from 172,416 a year earlier.
- Total lives under Clover management: 137,410.
Financial performance and liquidity
| Metric | Q1 2023 | Q1 2022 | Change |
|---|---|---|---|
| Total revenue | $527.8 million | $874.4 million | Down 39.6% |
| Premiums earned, net | $317.1 million | $278.2 million | Up 14.0% |
| Non-Insurance revenue | $205.8 million | $594.9 million | Down 65.4% |
| Net medical claims incurred | $472.5 million | $861.7 million | Down 45.2% |
| Gross profit | $55.3 million | $12.7 million | Improved |
| Loss from operations | $(72.6) million | $(87.5) million | Improved 17.0% |
| Net loss | $(72.6) million | $(75.5) million | Improved 3.8% |
| Basic and diluted loss per share | $(0.15) | $(0.16) | Improved |
| Net cash from operating activities | $79.0 million | $(57.0) million | Improved |
- Insurance medical care ratio was 86.6%, compared with 96.4% in Q1 2022. Non-Insurance MCR was 96.1%, compared with 99.8%.
- Total operating expenses were $600.4 million, including $70.2 million of salaries and benefits, $59.2 million of general and administrative expense, and $38.6 million of stock-based compensation.
- Cash and cash equivalents were $190.6 million at March 31, 2023. Including $82.7 million of restricted cash, short-term investments, and other investment securities, total restricted and unrestricted cash, cash equivalents, and investments were approximately $635.2 million.
- Total assets were $1.454 billion and stockholders’ equity was $323.1 million. Total liabilities were $1.130 billion.
- The filing reports no material changes to financing arrangements and no interest expense in Q1 2023. It does not identify material conventional debt outstanding.
- Management stated that available cash, investments, and projected operating cash flows are expected to meet projected operating and regulatory requirements for at least the next 12 months, although additional equity or debt financing may be required in the future.
Material changes versus the prior comparable period
- Premium revenue increased 14.0%, primarily due to higher CMS premiums associated with the 3.0-to-3.5 Star Rating and favorable risk-adjustment revenue.
- Non-Insurance revenue and related claims declined substantially following a strategic reduction in ACO REACH beneficiaries.
- Operating loss improved, but the company remained unprofitable. The prior-year period benefited from a $12.4 million gain on the Character Biosciences investment; no comparable gain was recorded in Q1 2023.
- The company adopted a change in accounting principle to include anticipated net investment income in calculating premium deficiency reserves. The change reduced the reported Q1 2023 reserve by approximately $6.9 million at March 31, 2023 and increased the Q1 2023 benefit by approximately $2.3 million versus the former method.
- Operating cash flow turned positive, helped by a $107.6 million CMS prepayment for April 2023, deferred revenue, working-capital movements, and non-cash stock compensation.
- Shares outstanding increased for Class A common stock and decreased for Class B common stock; treasury shares increased to 5.0 million, primarily from shares withheld for employee award taxes.
Guidance, outlook, risks, contingencies, and unusual items
- No formal revenue, earnings, or membership guidance is provided in the filing.
- On April 17, 2023, Clover announced a business transformation, including outsourcing certain plan operations to UST HealthProof under a services agreement running initially through December 31, 2028. The company also eliminated approximately 10% of its workforce.
- On April 20, 2023, Nasdaq notified Clover that its Class A stock had traded below the $1.00 minimum bid price for 30 consecutive business days. The company had until October 17, 2023 to regain compliance, with a possible additional compliance period subject to Nasdaq requirements. Management identified a potential reverse stock split as one possible alternative.
- On April 21, 2023, Clover entered into a memorandum of understanding to settle securities class-action litigation for $22 million, subject to definitive documentation and court approval. Insurers had advanced or committed $19.5 million, and Clover expected $2.5 million of out-of-pocket costs. The company had recorded a $2.5 million reserve at March 31, 2023.
- Derivative litigation and SEC-related investigations remain disclosed. The company stated that derivative claims were in preliminary stages and that an unfavorable outcome was not probable or estimable.
- The ACO REACH performance guarantee obligation was $613.1 million at March 31, 2023, offset by a $552.6 million performance-year receivable. The maximum future payment exposure cannot be estimated clearly because of stop-loss arrangements, risk ratings, benchmark trends, and other variables.
- Key risks include continued losses and cash requirements, medical-cost and claims-reserve estimation risk, regulatory and CMS program changes, Star Ratings, dependence on third-party vendors, litigation, potential Nasdaq delisting, and limits on dividends from regulated insurance subsidiaries.
Most important facts for investors to verify
- Whether the sharp reduction in ACO REACH beneficiaries improves sustainable economics or primarily reduces both revenue and claims volume.
- Whether the 86.6% Insurance MCR is sustained and whether medical-cost trends, risk adjustment, and Star Ratings support future margins.
- The timing and final terms of the UST HealthProof transition, workforce reductions, and expected cost savings.
- Nasdaq compliance actions, including any reverse stock split, additional compliance period, or delisting risk.
- Final approval and funding of the $22 million securities litigation settlement and any potential insurer recovery or recoupment claims.
- The adequacy of liquidity and statutory capital after claims payments, the ACO REACH performance guarantee, restructuring costs, and ongoing operating losses.
- The effect of $38.6 million of quarterly stock-based compensation and approximately $507.5 million of unrecognized stock-based compensation expense on future results and dilution.